GEN News Highlights: May 6, 2011

PerkinElmer Acquires Geospiza for Cloud-Based NGS Data Analysis and LIMS Platforms

PerkinElmer Acquires Geospiza for Cloud-Based NGS Data Analysis and LIMS Platforms

Firm claims products will allow "anytime, anywhere" genomic data interpretation and analysis.[Dmitry Sunagatov-Fotolia.com]

(Page 1 of 1)

    PerkinElmer has bought genetic analysis software firm Geospiza to get its hands on the latter’s flagship web-based GeneSifter® software for next-generation sequence analysis and LIMS. Back in January PerkinElmer inked a multiyear license agreement for Geospiza's GeneSifter Lab Edition and GeneSifter Analysis Edition software products but has now decided it is better off acquiring the firm outright.

    PerkinElmer says taking over the company will allow it to deliver an end-to-end solution comprising access to sequencing services as well as analysis and visualization software through cloud computing.

    “The acquisition of Geospiza along with existing software in our various diagnostic businesses gives PerkinElmer a strong platform for offerings in nucleic acid testing,” comments Richard Begley, Ph.D., president of emerging technologies at PerkinElmer. “Geospiza is a leader in its industry and a strong addition to PerkinElmer’s bioinformatics capabilities.”

    Geospiza’s flagship GeneSifter Lab Edition platform, formerly known as FinchLab, is an out-of-the-box lab management system for next-gen sequencing data management and analysis. The firm’s GeneSiftware Analysis Edition is a cloud-based data analysis product for microarray and next-gen sequencing data. The most recent release of GeneSifter Analysis Edition features splice index analysis and base variant calling for NGS as well as enhanced support for Affymetrix miRNA and Exon/Gene ST arrays.

    In February NIH’s  National Human Genome Research Institute awarded Geospiza a $1.2 million Phase II SBIR grant to collaborate with researchers at Weil Cornell Medical College  on development of a  new GeneSifter application that will allow rapid identification and visualization of DNA sequence variations between normal and cancer tissues.

    In March Geospiza inked a co-marketing deal with sample preparation specialist NuGEN through which the firms will develop and offer to clients an integrated workflow for next-generation sequencing sample preparation, data analysis, and sample information.


Related content

GEN News Highlights

Insight & Intelligence™

GEN Articles

BLOG biotech

Application Notes

Webinars

GEN Podcasts

New Products

Best of the Web

Subscription center

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe

e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.

 

All fields are required

Email
  Confirm Email
  First Name
  Last Name
  Organization
  E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll